Top Banner
Professor Stewart Cole FRS Chair of Microbial Pathogenesis Meeting of the ILEP Board & Technical Commission
13

Professor Stewart Cole FRS Chair of Microbial Pathogenesis

Feb 24, 2022

Download

Documents

dariahiddleston
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Page 1: Professor Stewart Cole FRS Chair of Microbial Pathogenesis

Professor Stewart Cole FRS Chair of Microbial Pathogenesis

Meeting of the ILEP Board & Technical Commission

Page 2: Professor Stewart Cole FRS Chair of Microbial Pathogenesis

2

Slide 12 Slide 12

Cole et al. (2001) 2

Page 3: Professor Stewart Cole FRS Chair of Microbial Pathogenesis

•  Drug susceptibility testing

•  Molecular epidemiology

•  Non-human sources of transmission

•  Perspectives for leprosy control

3

Page 4: Professor Stewart Cole FRS Chair of Microbial Pathogenesis

•  Limited DR reported, mainly in patients receiving inadequate therapy

•  Relapse cases usually DS •  DR assessed in vivo by MFP •  Or in vitro by radiometric method •  Both require viable bacilli & are slow, costly

& laborious •  Expertise has disappeared

4 4

Page 5: Professor Stewart Cole FRS Chair of Microbial Pathogenesis

•  Known resistance loci: – Rifampicin - rpoB gene (RNA polymerase

subunit β) – Dapsone - folP1 (Dihydropteroate synthase)

– Ofloxacin - gyrA (DNA gyrase)

5 5

Page 6: Professor Stewart Cole FRS Chair of Microbial Pathogenesis

•  Operating in 9 leprosy endemic countries: Brazil, China, Columbia, India, Myanmar, Pakistan, Philippines, Viet Nam and Yemen.

•  Standardized technical and operational procedures WHO “Guidelines for Global Surveillance of Drug Resistance in Leprosy” (SEA-GLP-2009.2).

•  10 reference labs: Brazil, France, Japan, Korea, India, Switzerland and USA

6 6

Page 7: Professor Stewart Cole FRS Chair of Microbial Pathogenesis

•  PCR amplification of target

•  ABI sequencing of rpoB, folP1 and gyrA loci

•  Biopsies and Slit-skin smear slides

•  No requirement for viability or cold chain

7 7

Page 8: Professor Stewart Cole FRS Chair of Microbial Pathogenesis

Ur1-1 (Uruguay)

Ur1-2 (Uruguay)

V2-1 (Venezuela)

V2-2 (Venezuela)

Maeda et. al 2001

ABI-sequence analysis of the RRDR region

of rpoB

85054 (Paris, Martinique)

TCG Ser

TTG Leu

TCG Ser

TCG Ser

TCG Ser

Page 9: Professor Stewart Cole FRS Chair of Microbial Pathogenesis

Drug & resistance target

Total number of M. leprae strains analyzed

Mutation in target

Rifampicin (rpoB) 219 0 Dapsone (folP1) 217 2 Ofloxacin (gyrA) 219 0

9 9

Page 10: Professor Stewart Cole FRS Chair of Microbial Pathogenesis

Maeda et. al Dec 2001

Ur1-1 Ur1-2 V2-1 V2-2 V2-3

85054 82073

Probe1: shows if sensitive to rifampicin (wild-type)

Probe2: shows if resistant to rifampicin (Ser>Leu mutation)

85054

82073

Ur1-1 Ur1-2 V2-1 V2-2 V2-3

RT-PCR analysis of the RRDR region

of rpoB

ΔR

n

ΔR

n

TTG Leu

10

Page 11: Professor Stewart Cole FRS Chair of Microbial Pathogenesis

•  Hain GenoType® MTBDRplus Assay

11 •  Similar test available for leprosy

Page 12: Professor Stewart Cole FRS Chair of Microbial Pathogenesis

•  MDST is rapid, sensitive, inexpensive and reliable

•  No other methods have equivalent capacity

•  MDST can be implemented at regional level

•  Valuable adjunct to control programmes

•  Must be used for all isolates

•  Combined with strain typing

12 12

Page 13: Professor Stewart Cole FRS Chair of Microbial Pathogenesis

•  Provides valuable epidemiological data

•  Fulfills sentinel role

•  Enables technology transfer

•  Builds & maintains capacity

•  Cost effective

•  Important global scientific activity

13